Tanya Gupta, MD, medical oncologist within the Stanford College Division of Drugs, Division of Medical Oncology, discusses the present panorama of antibody-drug conjugates (ADCs) for breast most cancers subtypes past HER2-positive illness.
Ado-trastuzumab emtansine (T-DM1; Kadcyla) for the remedy of HER2-positive illness was the primary to be accredited in 2013, adopted by fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd), which gained accelerated approval from the FDA for the remedy of grownup sufferers with unresectable or metastatic HER2-positive breast most cancers who had obtained 2 or extra prior HER2-targeted therapies within the metastatic setting.
Sacituzumab govitecan (Trodelvy) is a remedy choice that’s accredited for sufferers with superior triple-negative breast most cancers who’ve obtained 2 or extra prior systemic therapies, no less than 1 of which was within the metastatic setting, in addition to in hormone receptor-positive/HER2-negative superior illness given prior endocrine remedy and no less than 2 extra systemic therapies.
Transcription:
0:09 | There are a number of antibody-drug conjugates which have now been accredited, in addition to a number of antibody-drug conjugates which can be being studied within the area of breast oncology. The presently accredited antibody-drug conjugates are trastuzumab emtansine, often known as T-DM1, trastuzumab deruxtecan, often known as T-DXd, sacituzumab govitecan.
0:36 | In regard to your query about antibody-drug conjugates which can be getting used past the HER2-positive house, T-DXd and sacituzumab have indications outdoors of conventionally outlined HER2-positive illness. Particularly, T-DXd is utilized in HER2-low illness, which is a illness the place the immunohistochemistry result’s 1+ or 2+ IHC end result that’s detrimental. Sacituzumab is indicated each in triple detrimental breast most cancers and hormone receptor-positive, HER2-negative breast most cancers, each within the superior setting.
